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KAJIAN TENTANG MITRAGININA, ALKALOID UTAMA DARIPADA 
MITRAGYNA SPECIOSA KORTH (KRATOM) KE ATAS SIFAT-SIFAT 
PENYALAHGUNAAN DAN KETAGIHAN DALAM MODEL-MODEL 
TINGKAH LAKU TIKUS      
 
ABSTRAK 
 
Mitraginina adalah alkaloid aktif utama yang dipencil daripada daun 
Mitragyna speciosa atau kratom. Sementara mitraginina atau kratom menghasilkan 
kesan-kesan analgesik, anti-radang dan relaksi otot, namun sedikit yang telah 
diketahui tentang sifat-sifat penyalahgunaan dan penagihannya. Diberikan 
kemungkinan kepentingan sistem opioid dalam perantaraan kesan-kesan farmakologi 
mitraginina, kajian ini bertujuan meninjau kesan-kesan tingkah laku daripada 
mitraginina menggunakan tatacara pendiskriminasian drug dan pemberian sendiri 
drug. Tikus jantan jenis Sprague Dawley telah dilatih untuk mendiskriminasi antara 
mitraginina dan pembawa menggunakan tatacara pendiskriminasian drug dua tuil di 
bawah pembolehubah selang secara tandem (VI-60 saat) dan nisbah tetap (FR-10) 
dalam jadual pengukuhan makanan. Tikus-tikus itu telah berjaya memperoleh 
pendiskriminasian mitraginina (15.0 mg/kg, i.p.) yang mirip dengan kumpulan tikus 
yang satu lagi dengan pendiskriminasian morfina (5.0 mg/kg, i.p.)  Untuk 
memperoleh pemahaman yang lebih baik tentang penyerupaan farmakologi yang 
dikongsi antara mitraginina dan morfina, siri-siri ujian penukargantian yang serupa 
telah dijalankan pada tikus yang dilatih untuk mendiskriminasi morfina daripada 
pembawa. Mitraginina telah ditukargantikan sepenuhnya kepada rangsangan 
diskriminatif morfina dan sebaliknya, mencadangkan penyerupaan farmakologi di 
 
 
xxi 
 
antara kedua-dua jenis drug. Mekanisme farmakologi daripada derivatif mitraginina, 
7-hidroksimitraginina dengan fokus yang spesifik kepada penglibatan reseptor opioid 
juga telah diperiksa pada tikus-tikus yang dilatih untuk mendiskriminasi morfina 
daripada pembawa. Pemberian derivatif 7-hidroksimitraginina pada dos 3.0 mg/kg 
(i.p.) mengakibatkan penukargantian penuh kepada rangsangan diskriminatif 
morfina. Dalam usaha mengkaji kesan tindakan dual mitraginina, kesan 
penukargantian kokaina terhadap rangsangan diskriminatif mitraginina telah 
dijalankan pada tikus-tikus yang telah dilatih dengan mitraginina. Rangsangan 
mitraginina menunjukkan penukargantian separa ke atas rangsangan kokaina (10.0 
mg/kg, i.p.) manakala kesan ini tidak dapat dilihat dalam tikus-tikus yang dilatih 
untuk mendiskriminasi morfina daripada pembawa. Oleh kerana sifat-sifat subjektif 
yang menyerupai opioid dikesan melalui tatacara pendiskriminasian drug, kajian 
selanjutnya bertujuan untuk  menilai profil mitraginina dalam model tikus yang 
menunjukkan kebergantungan kepada fentanil (agonis μ-opioid) menggunakan 
tatacara dua tuil ‘pilihan’ pemberian sendiri drug. Mitraginina dalam tiga unit dos 
(0.3, 1.0 dan 3.0 mg/kg/infusi) telah mengekalkan gerak balas tekan tuil daripada 
pemberian sendiri fentanil (2.0 μg/kg/infusi). Profil sepanjang ujian saling 
penukargantian mitraginina berbeza daripada aras-aras garis dasar yang diperlihatkan 
dalam ujian-ujian pemupusan, lalu mencadangkan mitraginina mungkin mempunyai 
kesan-kesan pengukuhan. Keseluruhannya, kesan rangsangan diskriminatif dan 
potensi penghasilan kebergantungan yang ditunjukkan oleh mitraginina memberikan 
sebahagian bukti kepada potensi penyalahgunaan dan ketagihannya yang boleh 
menyokong pengelasan mitraginina atau kratom sebagai dadah yang berbahaya.  
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STUDIES OF MITRAGYNINE, THE PRINCIPLE ALKALOID OF 
MITRAGYNA SPECIOSA KORTH (KRATOM) ON ITS ABUSE AND 
ADDICTIVE PROPERTIES IN RAT BEHAVIOURAL MODELS 
 
ABSTRACT 
 
Mitragynine is the main active alkaloid isolated from the leaves of Mitragyna 
speciosa or kratom. While mitragynine or kratom provides analgesic, anti-
inflammatory and muscle relaxant effects, little is known about its abuse and 
addictive properties. Given the likely importance of opioid system in mediating the 
pharmacological effects of mitragynine, the present study aims to explore the 
behavioural effects of mitragynine using drug discrimination and drug self-
administration procedures. Male Sprague Dawley rats were trained to discriminate 
between mitragynine and vehicle in two-lever drug discrimination procedure under a 
tandem variable-interval (VI-60 sec) and fixed-ratio (FR-10) schedule of food 
reinforcement. The rats successfully acquired mitragynine discrimination (15.0 
mg/kg, i.p.) which was similar to another group of rats with morphine discrimination 
(5.0 mg/kg, i.p.). To gain a better understanding on the pharmacological similarities 
shared between mitragynine and morphine, a similar series of substitution tests were 
conducted in rats trained to discriminate morphine from vehicle. Mitragynine was 
fully substituted to the morphine discriminative stimulus and vice versa, suggesting 
pharmacological similarities between the two drugs. The pharmacological 
mechanism of mitragynine derivative, 7-hydroxymitragynine with a specific focus on 
opioid receptor involvement was also examined in rats trained to discriminate 
morphine from vehicle. The administration of 7-hydroxymitragynine derivative at 
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3.0 mg/kg (i.p.) dose engendered full substitution to the morphine discriminative 
stimulus. In order to study the dual actions of mitragynine, the effect of cocaine 
substitution to the mitragynine discriminative stimulus was performed in 
mitragynine-trained rats. The mitragynine stimulus was partially substituted to 
cocaine (10.0 mg/kg, i.p.) stimulus while this effect was not observed in rats trained 
to discriminate morphine from vehicle. Due to the ‘opioid-like’ subjective properties 
detected in drug discrimination model, further studies assessed the profile of 
mitragynine in rat model of fentanyl (i.e. µ-opioid agonist) dependence using two-
lever ‘choice’ of self-administration procedure. Mitragynine at three unit doses (0.3, 
1.0 and 3.0 mg/kg/infusion) maintained the lever-pressing responses of the fentanyl 
(2.0 μg/kg/infusion) self-administration. The profile over the mitragynine cross-
substitution tests was different from baseline levels observed during extinction tests, 
suggesting that mitragynine may have its reinforcing effects. Altogether, the 
discriminative stimulus effect and dependence-producing potential exhibited by 
mitragynine provide some evidence for its abuse and addictive potential, which may 
support the classification of mitragynine or kratom as a harmful drug.  
 
 
1 
 
CHAPTER 1 
 
INTRODUCTION 
 
It has been documented that natural products have contributed to 
development of new psychoactive drugs primarily due to pain relieving effects. 
Recently, new natural products appear with more than doubled over the period of 
2009 to 2013 on the drug markets (UNODC, 2014). The emerging search of new 
psychoactive drugs brings forward the long traditional use of the products to the 
global markets (Rosenbaum et al., 2012). Regardless of the efficacy of the products 
which are yet to be proven in controlled clinical trials, such products are being used 
extensively. Although they are considered safe due to their natural origins 
(Kronstrand et al., 2011), animal studies and clinical reports such as toxicity, adverse 
effects, as well as abuse-and addictive-related effects may indicate their potential 
risks to humans.  
 
One natural product that appears on the drug scene and gains widespread 
popularity in Malaysia is Mitragyna speciosa Korth or kratom (Adkins et al., 2011; 
Hassan et al., 2013). Mitragynine is the main active alkaloid extracted from the 
leaves of M. speciosa Korth (Shellard, 1974; Ponglux et al., 1994). For this reason, 
mitragynine is assumed to be the major chemical responsible for the effects of the 
plant. There are also other constituents of M. speciosa that may contribute to the 
effects which may involve 7-hydroxymitragynine, a minor constituent of the leaves 
extracts (Ponglux et al., 1994). Many scientific reports have indicated that 
mitragynine produces a variety of pharmacologic effects which include the induction 
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of analgesic effects (Matsumoto et al., 1996a; Stolt et al., 2014), inhibition of ileum 
motility (Watanabe et al., 1997) and vas deferens contractions of smooth muscle 
(Matsumoto et al., 2005b), as well as the inhibition of gastric acid secretion 
(Tsuchiya et al., 2002), which is consistent with the actions of morphine. In addition, 
studies with opioid receptor antagonists indicate that the effects are primarily 
mediated by the actions on opioid receptors (Matsumoto et al., 2005b; Watanabe et 
al., 1997).  
 
However, the psychoactive properties of M. speciosa appear to be 
contradictory as there are reports claiming it possesses both narcotic and stimulant 
properties (Assanangkornchai et al., 2007; Macko et al., 1972; Ward et al., 2011; 
Grewal, 1932a; Grewal, 1932b; Suwanlert, 1975, Reanmongkol et al., 2007). This 
suggests that kratom produces an unusual combination of opioid- and 
psychostimulant-like effects. Nevertheless, the pharmacological basis underlying the 
dual effects of mitragynine is still unclear. The stimulant and euphoric effects exerted 
by kratom caused the plant to be extensively misused as a herbal drug. Due to easy 
availability and cheap herbal preparation, kratom abuse has gained significant 
attention in Malaysia and Thailand (Chan et al., 2005). Furthermore, the wide 
availability of kratom to purchase through the internet reflects an increasing demand 
of misusing this herbal product globally (Boyer et al., 2008).  
 
The likelihood that a drug will be abused is generally based on the subjective 
and reinforcing effects exerted by the drug (Moser et al., 2011b). This has provided 
the framework for animal models of drug of abuse. Drug discrimination is used as a 
model to study the subjective effects of psychoactive drugs since the action of a 
drug’s discriminative stimulus in animals is closely related to its subjective effects in 
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human (Overton, 1988). Given that the action of mitragynine resembles morphine-
like (opioid) effects, it was hypothesised that mitragynine may share discriminative 
stimulus properties with morphine. Intravenous drug self-administration model is 
used to assess the reinforcing effects of drugs to reveal the reasons why humans 
abuse and become addicted to drugs (Shoaib, 2006). A cross-substitution experiment 
in which rats previously trained to self-administer intravenous injections of opioid 
will be presented with various doses of mitragynine. The dependence-producing 
potential of mitragynine from rat model of opioid dependence provides information 
on its potential reinforcing effects.  
 
The research to date has tended to focus on the effects of kratom on health, 
psychological, cognitive, behavioural and social impact (Macko et al., 1972; Moklas 
et al., 2008; Apryani et al., 2010; Idayu et al., 2011; Ahmad and Aziz, 2012; 
Sabetghadam et al., 2013a; Sabetghadam et al., 2013b; Yusoff et al., 2014) with little 
attention towards the assessment of abuse and addictive potential of the plant extracts 
or its active compounds. The present study addresses the assessment of abuse and 
addictive properties of the naturally occurring compound mitragynine, the major 
psychoactive constituent of M. speciosa Korth or kratom using rat behavioural 
models.  
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1.1   Problem statements 
 
 Kratom has been widely used for decades for both medical and non-medical 
purposes. Even though the efficacies are yet to be scientifically proven in humans, 
kratom is continued to be used extensively. The available human reports on kratom 
abuse and addictive properties have heightened the need for the assessment of its 
abuse and addictive potential.  
 
As a major constituent of M. speciosa, mitragynine is known as a 
psychoactive compound that produces major pharmacologic effects at opioid 
receptors. Most studies in the past decades have shown the resemblance of 
mitragynine towards morphine-like pharmacological characteristics. Thus, there is an 
increasing concern that mitragynine is being disadvantaged to the similar extent as 
the established opioid (i.e. morphine). Since drugs of abuse in humans produce 
subjective effects in experimental animals, there is a paucity of research whether 
mitragynine produces its subjective effects in rat behavioural models.  
 
 In addition, dual properties of opium-like (opioid) and coca-like 
(psychostimulant) effects demonstrated by mitragynine and kratom extracts represent 
the complexity in understanding their mechanisms of action. This situation raises an 
interest in elucidating the pharmacological similarity between mitragynine and 
opioid (i.e. morphine) and between mitragynine and psychostimulant (i.e. cocaine).  
 
 Besides mitragynine, 7-hydroxymitragynine also becomes another alkaloid of 
interest when it is reported as a minor psychoactive compound present in the plant. 7-
Hydroxymitragynine has been thought as another key component that contributes 
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towards the opium-like properties. Thus, it is suggested that the compound may also 
associate with the opioid discriminative stimulus effects.  
  
 In addition, drug abuse and addiction are often characterised by their 
reinforcing effects. The elucidation of mitragynine dependence-producing potential 
in opioid-dependent animals is warranted to provide information on its reinforcing 
effect.  
  
Last but not least, striking increases in the number of opioid users have 
expanded the need for pharmacotherapeutic interventions. Even though human 
reports and pre-clinical studies suggested potential valuable therapeutic properties of 
kratom, the neurobiological mechanism of using kratom as a substitution treatment 
amongst opioid addicts is still unclear. In fact, there is lack of scientific data to 
support the use of kratom as a potential substitution treatment. 
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1.2  Objectives of study 
 
 
Six specific objectives are constructed in this study in order to address the 
abovementioned problem statements: 
 
(i) To demonstrate the induction of mitragynine discrimination in rats 
 
(ii) To evaluate the substitutability of mitragynine to morphine and cocaine 
 
(iii) To evaluate the substitutability of morphine to mitragynine and cocaine 
 
(iv) To evaluate the effect of 7-hydroxymitragynine derivative on discriminative 
stimulus effect of morphine 
 
(v) To investigate the effect of naloxone, an opioid antagonist on discriminative 
stimulus effect of mitragynine, morphine and 7-hydroxymitragynine substituted 
responses 
 
(vi) To assess the dependence profile of mitragynine in a rat model of fentanyl 
self-administration 
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     Figure 1.1: The experimental design demonstrating the assessment of kratom abuse and  
addictive potential using two behavioural models 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1  Mitragyna speciosa Korth (kratom) 
 
 Mitragyna speciosa Korth is a tropical plant indigenous to Southeast Asia 
region particularly in Peninsular of Malaysia and Thailand (Jansen and Prast 1988a; 
Hassan et al., 2013). The plant is known as ‘biak-biak’ or ‘ketum’ in Malaysia and as 
‘kratom’ in Thailand (Jansen and Prast, 1988a; Adkins et al., 2011). It has been used 
as herbal stimulant by labourers and farmers in increasing work productivity during 
harsh conditions (Grewal, 1932a; Suwanlert, 1975; Hassan et al., 2013). The plant is 
known for decades as traditional herbal medicine for common illnesses such as 
diarrhoea, coughing, fever, malaria, muscle pain, as well as to improve blood 
circulation, sexual performance and to treat diabetes (Watanabe et al., 1997; Chan et 
al., 2005; Assanangkornchai et al., 2007; Kumarnsit et al., 2007a ; Chittrakarn et al., 
2010; Hassan et al., 2013).  
 
Apart from the energising and medicinal properties, kratom has been used as 
a substitute for opiate addiction due to the capability of suppressing opioid 
withdrawal symptoms (Wray, 1907; Suwanlert, 1975; Vicknasingam et al., 2010; 
Ahmad and Aziz, 2012). The earliest use of kratom substitution for opium was 
reported in Malaysia as early as 1895 (Wray, 1907; Burkill, 1935).  
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2.1.1 Botanical origin  
 
 Mitragyna speciosa Korth, as shown in Figure 2.1 belongs to the Rubiaceae 
family. The plants grow freely in swampy areas, fertile soil with sufficient sun 
exposure in regions that are protected from the strong winds (Shellard and Lees, 
1965; Macko et al., 1972; Hassan et al., 2013). They are large trunk trees which can 
grow up 4 to 9 metres height and 5 metres wide. The dark yellow flowers are 
globular in shape bearing up to 120 florets attached to the leaf axils on long stalks. 
The dark glossy green colour leaves normally grow to over 18 cm long and 10 cm 
wide with an ovate acuminate shape and tapered ends (Shellard and Lees, 1965; 
Hassan et al., 2013). The leaves will normally fall abundantly during hot season and 
grow intensely during rainy season (Macko et al., 1972). From all parts of the plant, 
the leaves are generally consumed (Jansen and Prast, 1988b; Kumarnsit et al., 2006; 
Hassan et al., 2013; Saingam et al., 2013) for their effects.  
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Figure 2.1: The plant of Mitragyna speciosa Korth (1) Leaves of the plant, (2) 
naturally occurring trees, (3) and (4) cultivated plants. Pictures are adopted from 
Hassan et al., (2013). 
 
2.1.2 Plant preparation and consumption 
 
 There are various ways to prepare kratom leaves. Some users simply chew 
the fresh leaves (Wray, 1907; Jansen and Prast, 1988a; Hassan et al., 2013) while 
some prefer kratom in the form of dried powder, in which they can smoke, swallow 
or prepare as tea for ingestion (Wray, 1907; Jansen and Prast, 1988a; Babu et al., 
2008). Locals will usually dry the leaves when kratom is abundance and use it as tea 
when there is a shortage of supply. The kratom users claim to experience no 
difference between the effects of fresh and dried leaves (Saingam et al., 2013; 
Sakaran et al., 2014). To make it easier for consumption, kratom is sold as drinks 
with a cheap price. In Malaysia, a small packet of the drink is sold at RM 1 (RM 1 = 
0.30 USD) (Chan et al., 2005; Ramanathan and Mansor, 2014). Sometimes, the 
drinks are consumed together with sugar or honey to mask their bitter taste. Lemon 
juice and salt are also added to facilitate the extraction of kratom leaves and prevent 
1 
4 3 
2 
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constipation respectively (Jansen and Prast, 1988a; Tanguay, 2011; Hassan et al., 
2013). In Southern Thailand, kratom is sometimes mixed with caffeine-containing 
soft drinks and codeine- or diphenhydramine-containing cough syrup to give the 
anxiolytic, antidepressant and analgesic effects (Tanguay, 2011; Hassan et al., 2013). 
Recently, kratom drink is mixed with some other toxics or addictive substances (i.e. 
cough medication, rat poison and mosquito coils) to increase the euphoric effects and 
give extra flavours to the drink (Saingam et al., 2013; Ramanathan and Mansor, 
2014).  
 
Nevertheless, many users tend to believe that kratom is not as harmful as 
other illicit drugs like heroin, morphine, cocaine, methamphetamine and etc. This 
may explain the increasing demand for kratom which not only observed in Malaysia 
and Southeast Asia countries but also in other parts of the world. In recent years, 
kratom has spread to Europe and United States where its products are readily 
available via internet, ranging from dried powder leaves to capsules, tablets and 
concentrated extracts (Boyer et al., 2007; Boyer and Wines, 2008). Kratom is also 
popular as a herbal blend krypton when it is mixed with O-desmethyltramadol, an 
active metabolite of a commonly prescribed analgesic (i.e. tramadol) to give more 
powerful effects (Backstrom et al., 2010; Kronstrand et al., 2011). The easy 
availability and cheap price of kratom compared to other illicit drugs reflect the wide 
spread of misusing the natural product (Boyer et al., 2007; McWhirter and Morris, 
2010; Adkins et al., 2011; Ramanathan and Mansor, 2014). The pictures of kratom 
consumption and several kratom products are shown in Figure 2.2A and Figure21.2B 
respectively. 
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Figure 2.2: (A) A kratom user chewing the kratom leaves. Picture is adapted from 
Matsumoto, (2006) (B) Products of kratom sold in the market. Pictures are adopted 
from Prozialeck et al. (2012). 
 
 
 
 
 
 
 
 
A 
B 
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2.1.3 Kratom consumption in humans 
 
 Typically, kratom is popular among elderly who find it beneficial for 
enhancing their physical energy and increasing work efficiency (Suwanlert, 1975; 
Vicknasingam et al., 2010; Saingam et al., 2013). Thus, people who consume kratom 
are regarded as better than those who abuse illicit drugs because they will become 
energetic while illicit drugs users usually feel lazy (Saingam et al., 2013). Besides, 
kratom users believe that their kratom practice is harmless and socially accepted as 
they do not disturb anyone which is opposite to the effects of illicit drugs 
(Assanangkornchai et al., 2007; Saingam et al., 2013). In fact, 99% of the kratom 
users still take a good care of their families (Ahmad and Aziz, 2012).  
 
In addition, kratom is also used as traditional herbal medication for various 
health disorders such as diabetes, hypertension, coughing, diarrhoea and muscle pain 
which enabling them for self-treatment (Suwanlert, 1975; Saingam et al., 2013). The 
knowledge of kratom as herbal medication is passed from generation to generation, 
keeping such treatment available to be practised (Saingam et al., 2013). Interestingly, 
the beneficial use of kratom is supported by recent pharmacological studies when 
kratom and its active constituents have demonstrated analgesic, antidiabetic and 
antidiarrheal effects, the morphine-like action on gastric acid secretion and reduction 
of morphine withdrawal symptoms in animal studies (Matsumoto et al., 1996b; 
Tsuchiya et al., 2002; Kumarnsit et al., 2007a; Reanmongkol et al., 2007; Khor et al., 
2011).  
 
 The Northern states of Malaysia (i.e. Kedah and Perlis), which are located at 
the border of Thailand have become a ‘redspot’ for kratom (Chan et al., 2005; Singh 
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et al., 2014). This leads to a cross-sectional survey done by Singh et al. (2014) to 
reveal various reasons of kratom use and the result is shown in Table 2.1. Majority of 
the respondents with 28% consumed kratom to increase their physical energy. There 
are about 15% of the respondents who consumed kratom to abstain from the effects 
of illicit drugs. Meanwhile, 13% of them consumed kratom as self-treatment for their 
medical problems. A small percentage (i.e. 6%) of the respondent claimed that 
kratom improved their mood, making them happy and relax. This finding coincides 
with previous reports when kratom users described the effects of ‘well-being’ or 
euphoria induction following kratom consumption (Jansen and Prast, 1988a; Jansen 
and Prast, 1988b; Assanangkornchai et al., 2007). Similar reasons of using kratom 
amongst the users were also reported in Thailand (Assanangkornchai et al., 2007; 
Saingam et al., 2013). 
 
Despite of its effects, about 21% of the respondents reported that they were 
using kratom due to curiosity and peer influence. This survey aligns with Thailand 
study when kratom users reported their initial use was due to curiosity and peer-
pressure (Assanangkornchai et al., 2007). This finding is supported by Saingam et al. 
(2013) where kratom is known amongst young people for fun or relaxation purposes.  
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Table 2.1: Reasons for using kratom in specific population at Northern Malaysia 
 
 
 
Respondent (n) 
     
(%) 
 
To enhance physical energy 
   
  83 
   
  28 
    
Curiosity                                                               61 21 
    
Peer influence  46 16 
    
To abstain from  illicit drugs/alcohol     45    15 
    
Self-treatment   38 13 
    
To improve mood/ease boredom 
 
To relieve fatigue                                                   
   17 
 
3 
6 
 
1 
    
 
Total 
 
 
 
293 
 
100 
 
* Adopted from Singh et al. (2014) 
 
 
2.1.4 Phytochemistry 
 
The chemistry of M. speciosa has been continuously studied for years. The 
investigation began in the 1920s when Hooper and Field first reported the isolation 
of mitragynine compound from M. speciosa leaves extracts (Field, 1921; Jansen and 
Prast, 1988a). However, the chemical structure of mitragynine was fully determined 
only almost 30 years later by Zacharias et al. (1965). A study by Shellard et al. 
(1974) later resulted in the isolation of over 25 alkaloids from various samples of M. 
speciosa leaves extracts. The main alkaloids present in the leaves of M. speciosa are 
mitragynine (12 to 66%) and its analogues that include paynantheine (9%), 
speciogynine (7%) and speciociliatine (1%) (Shellard, 1974; Hassan et al., 2013). A 
new analogue, 7-hydroxymitragynine was subsequently isolated as a minor 
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constituent (2%) (Ponglux et al., 1994). Kratom leaves contain approximately 0.2% 
mitragynine by weight of the total kratom leaves (Grewal, 1932a; Suwanlert, 1975). 
However, the mitragynine content was reported to vary by geographical region and 
season (Shellard, 1974; Hassan et al., 2013) as report shows that higher percentage of 
mitragynine (66%) of total alkaloid extracts of M. speciosa leaves was extracted 
from the leaves produced in Thailand compared to only 12% from the leaves 
extracted in Malaysia (Takayama, 2004).  
 
As the major constituent, mitragynine is assumed to be mostly responsible for 
the pharmacological effects of the plant extracts and this has led to an increased 
interest in characterising its chemical, toxicological and pharmacological properties 
in recent years (Macko et al., 1972; Shellard, 1974; Matsumoto et al., 1996a; 
Takayama et al., 2002; Takayama, 2004;  Matsumoto et al., 2005b; Reanmongkol et 
al., 2007; Azizi et al., 2010; Taufik Hidayat et al., 2010; Sabetghadam et al., 2013a). 
Structurally, mitragynine or 9-methoxy-corynantheidine (C23H30N204) with a 
molecular weight of 398.5 g/mol (Kumarnsit et al., 2007b) consists of a methoxy 
group at C19 position and C9 position of the indole ring (Beckett et al., 1966a; 
Beckett et al., 1966b; Shellard, 1974).  
 
Previous studies have reported that the antinociceptive effect of pure 
mitragynine was less potent than that of the crude extract of the plant (Watanabe et 
al., 1997; Yamamoto et al., 1999; Matsumoto et al., 2006) which suggested the 
presence of other active compounds in the total alkaloid extracts. This may involve 
7-hydroxymitragynine, the minor constituent of the leaves extracts. 7-
Hydroxymitragynine is the compound derived from mitragynine with the 
introduction of a hydroxyl group at the C7 position of the mitragynine skeleton 
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(Ponglux et al., 1994). This claim is supported by evidence that the antinociceptive 
effect of 7-hydroxymitragynine is relatively more potent than mitragynine 
(Matsumoto et al., 2004; Takayama, 2004). Thus, mitragynine and 7-
hydroxymitragynine are reported to be the most pharmacologically active, although 
the other constituents may also possess the pharmacological effects as listed in Table 
2.2.  
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Table 2.2: Structures and potential effects of alkaloids extracted from kratom 
Compound Percentage Structures 
Structures and pharmacological 
activities 
 
Mitragynine 
 
12-66% 
 
 
Structurally similar to yohimbine 
 
Analgesic, antitussive, anti-
diarrheal, adrenergic, 
antimalarial effects 
 
Activity on µ, δ and κ receptors 
 
Activates descending 
noradrenergic and serotonergic 
pathways in spinal cord 
 
Paynantheine 
 
9% 
 
 
Smooth muscle relaxant 
 
Inhibits twitch contraction 
without naloxone blocking effect 
 
Inhibits muscarinic receptors on 
smooth muscle 
 
Speciogynine 
 
7% 
 
 
Smooth muscle relaxant 
 
Inhibits twitch contraction 
without naloxone blocking effect 
 
Inhibits muscarinic receptors on 
smooth muscle 
 
Speciociliatine 
 
1% 
 
 
C3 stereoisomer of mitragynine 
 
Possess other than stimulation on 
opioid receptors i.e. may inhibit 
acetylcholine release from 
presynaptic nerve 
 
7-hydroxy 
mitragynine 
 
2% 
 Possess –OH group on C7 
position 
 
Analgesic, antitussive, anti-
diarrheal effects 
 
Higher opioid agonist potency 
than mitragynine and morphine 
Note: Percentage denotes the percentages (%) of the compound in the alkaloid 
fraction/extract 
*Adopted from Hassan et al. (2013) 
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2.1.5 Pharmacokinetics 
 
 The quantification analyses of kratom alkaloids in the biological systems are 
fundamental in order to provide better understanding of the pharmacological activity 
of its extracts. The pharmacokinetic of mitragynine was well characterized in rat 
plasma following oral and intravenous administrations. Oral administration of 40 
mg/kg of mitragynine in rats led to a peak plasma concentration (Cmax) of 0.63 μg/ml 
after Tmax of 1.83 h (Janchawee et al., 2007) using a High Performance Liquid 
Chromatography-Ultra Violet (HPLC/UV) method. In the following study using 
HPLC and tandem mass spectrometry (LC-MS/MS), mitragynine was reported to be 
rapidly absorbed with a maximum concentration (Cmax) of 423.68 ng/ml and a Tmax 
of 1.26 h after oral administration of 20 mg/kg mitragynine. The elimination half-life 
(t1/2) was shown to be 3.85 h (de Moraes et al., 2009). A pharmacokinetic study done 
by Parthasarathy et al. (2010) using solid-phase extraction and rapid HPLC-UV 
analysis reported that oral administration of 50 mg/kg dose of mitragynine resulted in 
the Cmax of 0.7±0.21 μg/ml and the Tmax of 4.5 ± 3.6 h. The elimination half-life (t1/2) 
was 2.9 ± 2.1 h. The variations of the pharmacokinetic profiles observed from these 
studies could be attributed by poor oral absorption of mitragynine.  
 
 Meanwhile, following intravenous administration of 1.5 mg/kg, the Cmax was 
reported to be 2.3 ± 1.2 μg/ml with Tmax of 1.2 ± 1.1 h and elimination half-life (t1/2) 
was determined at 2.9 ± 2.1 h (Parthasarathy et al., 2010). In contrast, a more recent 
pharmacokinetic study using ultra-performance liquid chromatography-mass 
spectrometry (UPLC-MS) reported the Cmax of 3.9 ± 0.7 μg/ml at 1 min following the 
administration of 5 mg/kg mitragynine while the elimination half-life (t1/2) was 2.6 ± 
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0.6 h (Vuppala et al., 2011). However, it is important to note that the 
pharmacokinetic on multiple dose study of mitragynine has yet to be reported.  
 
 
2.1.6 Toxicity studies in animals 
 
The earliest acute toxicity report of mitragynine by Macko et al. (1972) found 
no absolute evidence of toxicity, whereby no tremors or convulsions were observed 
at the doses as high as 920 mg/kg in mice. However, a recent study by Janchawee et 
al. (2007) demonstrated lethal effects after an oral administration of 200 mg/kg 
mitragynine in rats. The similar fatal effect was also observed after administration of 
200 mg/kg alkaloid extract of M. speciosa to rats (Azizi et al., 2010).  
 
The earliest sub-acute toxicity study by Macko et al. (1972) demonstrated no 
side effects in rats after administration of 5 or 50 mg/kg/day of mitragynine for five 
days per week within six weeks duration. There was only a significant decrease in 
liver and kidney weights that were observed at higher mitragynine dose. Similarly in 
dogs, no side effects were observed following 20 mg/kg of mitragynine 
administration per day for three weeks duration. However, hematological findings 
including leukopenia, lymphocytosis, granulocytopenia, monocytosis and immature 
lymphocytes were observed in dogs from day 22 when the dose was increased to 40 
mg/kg/day for six days per week. In fact, these changes were reversed after the drug 
was withdrawn. A most recent sub-chronic study by Sabetghadam et al. (2013b) 
demonstrated no mortality or toxic effects in mice after administered at low or 
intermediate dose (i.e. 1 and 10 mg/kg) of mitragynine. However, decreases in food 
intake and body weight were observed at the highest mitragynine dose (i.e. 100 
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mg/kg). Overall, the previous reports suggested that mitragynine is relatively safe at 
low sub-chronic doses (i.e. 1 to 10 mg/kg), but exhibits toxicity at higher sub-chronic 
dose (i.e. 100 mg/kg at 28 days) (Sabetghadam et al., 2013b). Nevertheless, 
information about the dose level that could be translated from animal data to human 
perspectives is still lacking.   
 
 
2.1.7 Toxicity and adverse effects in humans 
 
Several human studies and case reports also emerged to provide evidence of 
long term toxicity and adverse effects of kratom preparations. The first study of 
mitragynine in humans was reported by Grewal (1932b) when some of the human 
subjects developed nausea, vomiting, slide tremors of the hand and tongue, 
giddiness, feeling of haziness and slight flushing of the face following mitragynine 
administration. It was reported that a man who tried to abstain from kratom had 
difficulty to sleep, wriggling sensation in the shoulders and the back, dragging 
sensation in the hips, bitemporal headache, became extremely weak and also could 
hardly walk (Thuan, 1957). A recent study by Vicknasingam and colleagues (2010) 
also revealed that kratom produced mild side effects such as loss of weight, 
dehydration, constipation but no other medical problems were reported. However, 
prolonged use of kratom was reported to cause adverse effects which include nausea, 
diarrhoea, vomiting, hallucinations, psychosis, agitation, dizziness, itching, sweating, 
dry mouth, respiratory depression, constipation, anorexia, increased urination, 
palpitations and weight loss (Suwanlert, 1975; Jansen and Prast, 1988a; Babu et al., 
2008; Adkins et al., 2011; Prozialeck et al., 2012).  
 
22 
 
Other than adverse effects, there are no reports of mortalities following 
mitragynine or kratom consumption alone, even after chronic and high dosage 
consumption (Ramanathan and Mansor, 2014). However, the combination of kratom 
with other drugs (i.e. krypton) (Backstrom et al., 2010; Hassan et al., 2013) had 
contributed to unintended death (Kronstrand et al., 2011). A similar fatal case was 
also reported following the co-ingestion of propylhexedrine and mitragynine (Holler 
et al., 2011). Even though the contribution of kratom or its active compound, 
mitragynine to the unintended deaths remain unclear, the adulterated form of kratom 
products could contribute to its multidrug actions. To date, little is known about the 
clinical effects and the potential toxicities of mitragynine or kratom in humans. The 
available reports in humans may suggest the potential adverse effects at extremely 
high dosage of mitragynine or kratom consumption. However, there are no precise 
studies on mitragynine or kratom dose ranges that are responsible for those effects at 
present. 
 
 
2.1.8 Metabolism 
 
 Mitragynine is extensively metabolised in rats and humans. This mechanism 
involved the hydrolysis of the methylester in position C16, O-demethylation of the 9-
methoxy group and of the 17-methoxy group followed by oxidation and reduction 
reactions from the intermediate aldehydes to form carboxylic acids and alcohol, 
respectively. Finally, four phase 1 metabolites were conjugated to form four 
glucuronides and one sulphate in rats while the conjugation resulted in three 
glucoronides and three sulphates in humans (Philipp et al., 2009). Previous report has 
demonstrated that M. speciosa extract showed the most potent inhibition on 
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cytochrome P450 enzyme (i.e. CYP 2D6) with IC50 value of 3.6 ± 0.1 µg/ml 
suggesting that the consumption of the extract together with other drugs that have the 
same metabolic pathway may contribute to herb-drug interactions (Hanapi et al., 
2010). This finding possibly suggests that the mixture of kratom preparations with 
other psychoactive drugs may lead to overdose and adverse effects.  
 
 
2.1.9 Opioid agonist property 
 
 Opioid is any chemicals that possessed opiate-like pharmacological effects. 
An opiate is a plant-derived material product from opium poppy (Papaver 
somniferum) (Van Ree et al., 1999). The seed capsule of the poppy contains 
morphine, codeine and other alkaloids. The clinical benefits of opioid as a pain-relief 
agent led to the development of synthetic opioid medications such as methadone, 
heroin and fentanyl (Linneman et al., 2000; Walwyn et al., 2010). Thus, the term 
opiates arise in describing any of the psychoactive opioid compounds with opioid-
agonistic function (Van Ree et al., 1999). Opioids exert their effects by binding to 
opioid receptor subtypes (i.e. μ-, δ- and κ- receptors) that are distributed in the 
central and peripheral nervous systems (Quock et al., 1999).  
 
The opioid-like properties of mitragynine was assessed using the twitch 
contraction of guinea pig ileum induced by electrical stimulation (Watanabe et al., 
1997). The inhibitory effect of mitragynine on gastric acid secretion was well 
demonstrated in rats when injection of mitragynine into the fourth cerebroventricle 
inhibited the 2-deoxy-D-glucose-stimulated gastric acid secretion. Interestingly, this 
inhibitory effect was reversed by naloxone, suggesting the inhibitory effects 
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possessed by mitragynine were mediated by the opioid system which was similar to 
morphine (Tsuchiya et al., 2002). Besides, the opioid receptor agonistic effect of 
mitragynine was also reported in other studies (Matsumoto et al., 1996b; Watanabe 
et al., 1997; Yamamoto et al., 1999; Boyer et al., 2008; Taufik Hidayat et al., 2010). 
In addition, mitragynine was also reported to produce antinociceptive activity 
through supraspinal opioid receptors when its antinociceptive activities following 
intraperitoneal (i.p.) and intracerebroventrical (i.c.v.) administrations were 
antagonised by i.c.v. naloxone in both tail-pinch and hot-plate tests (Matsumoto et 
al., 1996b). 
 
Besides, competitive binding studies showed the involvement of three types 
of opioid receptors in mitragynine effect, which include µ-, κ- and δ- opioid 
receptors (Yamamoto et al., 1999; Boyer et al., 2008; Taufik Hidayat et al., 2010). 
From the three receptor subtypes, mitragynine was shown to exert most of its effects 
via µ-opioid receptor (Matsumoto et al., 1996b; Thongpradichote et al., 1998; 
Shamima et al., 2012; Stolt et al., 2014). In addition, receptor binding assays also 
demonstrated that 7-hydroxymitragynine bound preferentially to µ-opioid receptors, 
suggesting its full agonistic properties (Takayama et al., 2002; Matsumoto et al., 
2004). Taken together, mitragynine and its 7-hydroxymitragynine derivative are 
reported to act on the central nervous system (CNS) and exhibit high affinities 
toward µ-opioid receptor (Yamamoto et al., 1999; Matsumoto et al., 2006).  
 
 
 
 
